La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

T. Di Paolo And NotHippocampe

List of bibliographic references

Number of relevant bibliographic references: 26.
Ident.Authors (with country if any)Title
000137 S. Al Sweidi [Canada] ; M. G. Sanchez [Canada] ; M. Bourque [Canada] ; M. Morissette [Canada] ; D. Dluzen [États-Unis] ; T. Di Paolo [Canada]Oestrogen Receptors and Signalling Pathways: Implications for Neuroprotective Effects of Sex Steroids in Parkinson's Disease
000384 B. Ouattara [Canada] ; D. Hoyer [Suisse] ; L. Gregoire [Canada] ; M. Morissette [Canada] ; F. Gasparini [Suisse] ; B. Gomez-Mancilla [Suisse] ; T. Di Paolo [Canada]CHANGES OF AMPA RECEPTORS IN MPTP MONKEYS WITH LEVODOPA-INDUCED DYSKINESIAS
000937 A. Hadj Tahar [Canada] ; R. Grondin [Canada] ; L. Gregoire [Canada] ; F. Calon [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada]New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable
000B60 M. Goulet [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; S. Maltais [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada]Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys
000B68 M. Grandbois [Canada] ; M. Morissette [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada]Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice
000B96 M. Cyr [Canada] ; F. Calon [Canada] ; M. Morissette [Canada] ; M. Grandbois [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada]Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS
000C13 F. Calon [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; R. Grondin [Canada] ; P. J. Blanchet [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada]125I-CGP 64213 binding to GABAB receptors in the brain of monkeys : Effect of MPTP and dopaminomimetic treatments
000C62 R. Grondin [Canada] ; M. Goulet [Canada] ; M. Morissette [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada]Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958
000C69 F. Calon [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; R. Grondin [Canada] ; P. J. Blanchet [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada]Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys : effects on basal ganglia GABAA/ benzodiazepine receptor complex and GABA content
000D94 M. Goulet [Canada] ; M. Morissette [Canada] ; F. Calon [Canada] ; P. J. Blanchet [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada]Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression : In situ hybridization histochemical analysis
000E22 J.-J. Soghomonian [Canada] ; S. Pedneault [Canada] ; P. J. Blanchet [Canada] ; M. Goulet [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada]L-DOPA regulates glutamate decarboxylases mRNA levels in MPTP-treated monkeys
000E28 M. Goulet [Canada] ; R. Grondin ; P. J. Blanchet ; P. J. Bedard ; T. Di Paolo [Canada]Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode to not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys
000E36 R. Grondin [Canada] ; M. Goulet [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada]Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates
000E58 F. Calon [Canada] ; M. Goulet [Canada] ; P. J. Blanchet ; J. C. Martel [Canada] ; M. F. Piercey ; P. J. Bedard ; T. Di Paolo [Canada]Levodopa or D2 agonist induced dyskinesia in MPTP monkeys : correlation with changes in dopamine and GABAA receptors in the striatopallidal complex
000E60 P. J. Blanchet ; B. Gomez-Mancilla [Canada] ; T. Di Paolo ; P. J. BedardIs striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia ?
000E66 C. Gagnon [Canada] ; B. Gomez-Mancilla ; R. Markstein ; P. J. Bedard ; T. Di Paolo [Canada]Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys : regional changes of brain dopamine receptors
000F44 B. Gomez-Mancilla [Canada] ; R. Boucher ; C. Gagnon ; T. Di Paolo ; R. Markstein ; P. J. BedardEffect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors
000F50 C. Gagnon [Canada] ; B. Gomez-Mancilla ; P. J. Bedard ; T. Di Paolo [Canada]Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors
000F59 L. Rioux [Canada] ; C. Gagnon ; D. P. Gaudin [Canada] ; T. Di Paolo ; P. J. Bedard [Canada]A fetal nigral graft prevents behavioral supersensitivity associated with repeated injections of L-dopa in 6-OHDA rats. Correlation with D1 and D2 receptors
001063 C. Rouillard ; P. J. Bedard ; T. Di PaoloEffects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393
001064 C. Gagnon ; P. J. Bedard ; T. Di PaoloEffect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists
001071 C. Harnois ; T. Di PaoloDecreased dopamine in the retinas of patients with Parkinson's disease
001097 C. Harnois ; G. Marcotte ; T. Di PaoloDifferent sensitivities to MPTP toxicity in primate nigrostriatal and retinal dopaminergic systems: electrophysiological and biochemical evidence
001126 P. Falardeau ; S. Bouchard ; P. J. Bedard ; R. Boucher ; T. Di PaoloBehavioral and biochemical effect of chronic treatment with D-1 and/or D-2dopamine agonists in MPTP monkeys
001171 T. Di Paolo ; P. Bedard ; M. Daigle ; R. BoucherLong-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys
001184 P. J. Bedard ; T. Di Paolo ; P. Falardeau ; R. BoucherChronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-Parkinsonian monkeys. Correlation with [3H]spiperone binding

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022